drugset / Trial / NCT01174030
Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this vehicle controlled study is to evaluate the efficacy and safety of CD07805/47 gel 0.5% applied topically once daily (QD) for 4 weeks, and CD07805/47 gel 0.18% applied topically once daily (QD) or twice daily (BID) for 4 weeks, in subjects with moderate to severe facial erythema associated with rosacea.
Timeline
- Start
- 2010-08
- Primary completion
- 2010-12
- Completion
- 2011-01
Outcome
Mixed primary results
registry CD07805/47 Gel 0.5% QD vs Vehicle Gel QD; p <0.001; Odds Ratio (OR) 8.392 (95% CI 2.637 to 26.710) NCT01174030 ↗
registry CD07805/47 Gel 0.18% QD vs Vehicle Gel QD; p = 0.027; Odds Ratio (OR) 3.738 (95% CI 1.097 to 12.742) NCT01174030 ↗
registry CD07805/47 Gel 0.18% BID vs Vehicle Gel BID; p = 0.549; Odds Ratio (OR) 1.269 (95% CI 0.586 to 2.747) NCT01174030 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brimonidine | Unknown | 0.18 % | Topical |
| Subject | Brimonidine | Unknown | 0.5 % | Topical |